Birchbrook Inc. Boosts Stock Holdings in IQVIA Holdings Inc. $IQV

Birchbrook Inc. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,187 shares of the medical research company’s stock after acquiring an additional 619 shares during the period. Birchbrook Inc.’s holdings in IQVIA were worth $660,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares in the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA during the first quarter valued at $33,000. Trust Co. of Toledo NA OH purchased a new position in IQVIA in the 2nd quarter worth about $39,000. J.Safra Asset Management Corp lifted its stake in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 169 shares during the period. Finally, Rothschild Investment LLC boosted its holdings in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Redburn Partners set a $214.00 price objective on shares of IQVIA in a report on Wednesday, September 3rd. Stifel Nicolaus boosted their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Cowen cut IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $240.61.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Trading Up 0.7%

NYSE:IQV opened at $217.60 on Wednesday. The firm has a market capitalization of $37.06 billion, a price-to-earnings ratio of 29.85, a price-to-earnings-growth ratio of 2.43 and a beta of 1.34. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The business has a fifty day moving average price of $203.84 and a 200-day moving average price of $179.79. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the previous year, the company posted $2.84 earnings per share. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.